Market revenue in 2023 | USD 31.7 million |
Market revenue in 2030 | USD 43.7 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.69% in 2023. Horizon Databook has segmented the Sweden point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Cancer is one of the leading causes of mortality in Sweden. According to Globocan 2020, 24,464 cancer deaths occurred in the country, and approximately 62,494 new cancer cases were diagnosed. The Swedish government introduced the new EU Cancer Plan to reduce the burden of cancer. This plan emphasized improving the treatment of cancer.
This was expected to improve the demand for molecular diagnostics for use in cancer over the forecast period. However, the negative CAGR of the market is attributable to the impact of COVID-19. The country’s precision medicine industry has received significant investments recently.
For instance, in September 2021, Swedish national infrastructure Genomic Medicine Sweden (GMS) received USD 25.6 million in funding for developing precision medicine therapeutics. Such strategies are likely to improve the demand for molecular diagnostics for clinical studies in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Sweden point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account